Resource Summary Report

Generated by RRID on Aug 28, 2026

NK-92MI

RRID:CVCL_3755
Type: Cell Line

Proper Citation

KCB Cat# KCB 200677YJ, RRID:CVCL_3755

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3755

Proper Citation: KCB Cat# KCB 200677YJ, RRID:CVCL_3755

Description: Cell line NK-92MI is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: PMID:10365666, PMID:27397505, PMID:30894373, PMID:35839778

Comments: Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NK-92MI

Synonyms: NK-92 MI, NK-92 mi, NK92-MI, NK92MI, NK-92 transfected with MFG-hIL2

Cross References: CLO:CLO_0008178, ATCC:CRL-2408, BCRC:60438, cancercelllines:CVCL_3755, CCRID:1102HUM-NIFDC00065, Cell_Model_Passport:SIDM01201, Cosmic-CLP:1330981, DepMap:ACH-002289, GDSC:1330981, GEO:GSM1670278, KCB:KCB 200677YJ, LINCS_LDP:LCL-1127,

PharmacoDB:NK92MI_1160_2019, PRIDE:PXD030304, Wikidata:Q54930658

ID: CVCL_3755

Vendor: KCB

Catalog Number: KCB 200677YJ

Hierarchy: cvcl_2142

Record Creation Time: 20250130T072536+0000

Record Last Update: 20260816T001410+0000

Ratings and Alerts

No rating or validation information has been found for NK-92MI.

Warning: Discontinued: BCRC; 60438
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line. Warning: Discontinued: ATCC; PTA-6671
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Yuan M, et al. (2026) Triple-Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells' Function and Facilitate Cancer Metastasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e75655.

Su Q, et al. (2026) Galectin-1-Targeted Type-I/II Photosensitizers Activate the NF-??B Pathway to Enhance Immunity and Treat High-Risk HPV-Associated Cervical Lesions. ACS applied materials & interfaces, 18(2), 3599.

Gunnels TF, et al. (2026) CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins. bioRxiv : the preprint server for biology.

Shao N, et al. (2026) A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. Microsystems & nanoengineering, 12(1).

Seijo-Vila M, et al. (2026) Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response. Oncogene, 45(25), 2436.

Brennan K, et al. (2026) Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. Cell reports. Medicine, 7(6), 102792.

Chen L, et al. (2025) Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma. Pharmaceuticals (Basel, Switzerland), 18(5).

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell reports. Medicine, 6(3), 101975.

Lin YY, et al. (2025) Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1. Theranostics, 15(10), 4308.

Cheng C, et al. (2025) Dual roles of TRPV2 in the innate immune response to cytosolic DNA: Arresting dormant and boosting activated STING. Cell reports, 45(1), 116745.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity, 57(12), 2863.

Guo S, et al. (2024) CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood advances, 8(11), 2635.

Teng HW, et al. (2024) CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. Molecular oncology.

Schober R, et al. (2023) Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure. Journal of translational medicine, 21(1), 791.

Kong Q, et al. (2023) Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Science immunology, 8(82), eadg3196.

Perez-Hernandez D, et al. (2023) An integrated workflow for phosphopeptide identification in natural killer cells (NK-92MI) and their targets (MDA-MB-231) during immunological synapse formation. STAR protocols, 4(1), 102104.

Lu YC, et al. (2023) NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy. Molecular oncology.

Gong YY, et al. (2022) Na+/H+-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells. Cancer research communications, 2(8), 842.

Figueroa-Romero C, et al. (2022) Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis. Frontiers in immunology, 13, 773288.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.